Diabetic Peripheral Neuropathy: Nerve Conduction Studies Before, During and After Carbamazepine Therapy

Chakrabarti, Amitava; Samantaray, Sagarika

doi:10.1111/j.1445-5994.1976.tb03996.x

Cited by 45 publications

(10 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, failure of improvement in NCV by pregabalin has been reported by others also [28]. A study conducted in India has also described the similar findings for carbamazepine [29]. On the other hand, a meta-analysis conducted for alpha-lipoic acid has showed significant improvement in NCV [30].…”

Section: Discussionmentioning

confidence: 64%

A study of the use of carbamazepine, pregabalin and alpha lipoic acid in patients of diabetic neuropathy

Patel¹,

Mishra²,

Patel

et al. 2014

J Diabetes Metab Disord

View full text Add to dashboard Cite

BackgroundDiabetic peripheral neuropathy (DPN) is a common, symptomatic, long-term complication of diabetes mellitus. Many of the agents used to treat DN have not been compared with each other. This study was, therefore, undertaken to compare the efficacy and safety of carbamazepine, pregabalin and alpha-lipoic acid in diabetic neuropathy patients.MethodsThis was a prospective, observational study. The patients were categorized into three groups, Group I included those patients who were prescribed carbamazepine while group II included those on pregabalin and group III patients received alpha-lipoic acid. Each patient was followed up at every month for total duration of 6 months. Demographic details, presenting symptoms, history of diabetes, laboratory values pertaining to diabetes (Fasting blood sugar, Post prandial blood sugar and HbA1c) were recorded. Intensity of pain, using a visual analogue scale (VAS), diabetic neuropathy symptom (DNS) score and diabetic neuropathy examination (DNE) score were assessed at baseline and then at each monthly follow-up. Nerve conduction velocity (NCV) was also measured at baseline and then at the end of 3 and 6 months.ResultsA total of 101 patients were enrolled out of them 96 completed the study. Regarding VAS, the number of patients having pain was reduced substantially however, the speed and the quantum of this reduction were best in group II (pregabalin). Regarding DNS, also group II showed the best response in terms of number of patients as well as the speed of improvement. The results also imply that the relief from diabetic neuropathy (as per DNE score) is superior with pregabalin administration. However, no improvement in NCV was evident in any group.ConclusionResults of this study suggest that treatment with pregabalin gives faster and better improvement in diabetic neuropathy.

show abstract

Section: Discussionmentioning

confidence: 64%

A study of the use of carbamazepine, pregabalin and alpha lipoic acid in patients of diabetic neuropathy

Patel¹,

Mishra²,

Patel

et al. 2014

J Diabetes Metab Disord

View full text Add to dashboard Cite

show abstract

“…The anticonvulsants carbamazepine[134–137], phenytoin[138–140], clonazepam[101] and sodium valproate[63] have been studied in diabetic neuropathic pain. However, only four of these studies have been randomized placebo‐controlled trials[134, 135, 139, 140].…”

Section: Management Of Neuropathic Painmentioning

confidence: 99%

Painful diabetic neuropathy

1999

View full text Add to dashboard Cite

Summary Chronic painful diabetic neuropathy causes symptoms that can last for many years and severely impair the quality of life of affected patients. This review describes the epidemiology, pathophysiology and treatment of chronic neuropathic pain. Particular emphasis is placed on a comprehensive review of the management of painful symptoms through a detailed review of the published literature using a variety of databases particularly Medline and EMBASE.

show abstract

“…Older studies [58][59][60][61] found that carbamazepine was beneficial in one study, although the patients had a variety of neuropathic syndromes [58], two were not RCT [60,61] and the fourth was very brief [59]. The NNT for the positive study [58] was 3.3.…”

Section: Carbamazepinementioning

confidence: 99%